The Price is Wrong: Finding Alternatives to Traditional IPOs
This article was originally published in Start Up
Executive Summary
Biotech IPO pricing is fraught with more uncertainty than ever before, say some private investors and executives. It's worth seriously considering the alternatives. Start-Up takes a look at what is wrong with IPO pricing and how alternatives such as reverse mergers, M&A, or Dutch auction IPOs can improve biotech valuations.